

## Acuvi - Weak top-line but strong pipeline

Redeye remains confident in the case despite a slow start into 2023 in terms of top-line growth. Q1 sales were flat Y/Y, but down when adjusted for currency effects. On a positive note, gross margins held up very well. We believe Acuvi has a solid business pipeline and expect a pickup in sales during the year. Our valuation is negatively impacted by more cautious assumptions on sustainable margins.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Acuvi - Weak top-line but strong pipeline**